89bio, Inc (ETNB)

Etorro trading 970x250
89bio, Inc (ETNB) Logo

About 89bio, Inc

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California. Address: 142 Sansome Street, San Francisco, CA, United States, 94104

89bio, Inc News and around…

Latest news about 89bio, Inc (ETNB) common stock and company :

Insiders at 89bio, Inc. (NASDAQ:ETNB) recouped some losses this week after buying this year, still down US$20k
15 Aug, 2022 Yahoo! Finance

Insiders who purchased US$53k worth of 89bio, Inc. ( NASDAQ:ETNB ) shares over the past year recouped some of their...

Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
15 Aug, 2022 FinancialContent

Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported ...

Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session
12 Aug, 2022 FinancialContent

Gainers Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over ...

Recap: 89bio Q2 Earnings
11 Aug, 2022 FinancialContent

89bio (NASDAQ:ETNB) reported its Q2 earnings results on Thursday, August 11, 2022. Here's what investors need to know ...

89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
11 Aug, 2022 Yahoo! Finance

- Reported positive topline results from ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia patients; initiation of Phase 3 trial expected in the first half of 2023 - - ENTRIGUE data to be presented as a late-breaker at European Society of Cardiology Congress 2022 - - ENLIVEN Phase 2b NASH trial enrollment completion expected in the third quarter of 2022 followed by topline data in the first quarter of 2023 - - Completed underwritten offering, raising approximately $94.5 milli

Expert Ratings for 89bio
28 Jul, 2022 FinancialContent

Analysts have provided the following ratings for 89bio (NASDAQ:ETNB) within the last quarter: Bullish Somewhat ...

RYJ's Underlying Holdings Imply 47% Gain Potential
26 Jul, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Raymond James SB-1 Equity ETF (RYJ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $79.52 per unit.

This Analyst Thinks 89Bio's Pegozafermin Data Has Exceeded Expectations
11 Jul, 2022 FinancialContent

In June,89bio Inc(NASDAQ: ETNB)announced topline resultsfrom the ENTRIGUE Phase 2 proof-of-concept study of ...

The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill
07 Jul, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Potential Buyout ...

What Kind Of Shareholders Hold The Majority In 89bio, Inc.'s (NASDAQ:ETNB) Shares?
05 Jul, 2022 Yahoo! Finance

A look at the shareholders of 89bio, Inc. ( NASDAQ:ETNB ) can tell us which group is most powerful. Large companies...

89bio Announces Closing of its Upsized $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
05 Jul, 2022 Yahoo! Finance

SAN FRANCISCO, July 05, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the closing of its upsized underwritten public offering of 18,675,466 shares of its common stock and accompanying warrants to purchase up to 9,337,733 shares of common stock at a combined public offering price of $3.55 and,

Disney To $125? Here's The Biggest Price Target Changes For Thursday
30 Jun, 2022 FinancialContent

Stifel cut SMART Global Holdings, Inc. (NASDAQ: SGH) price target from $45 to $32. SMART Global shares fell 13.1% to $17.62 in ...

5 Analysts Have This to Say About 89bio
29 Jun, 2022 FinancialContent

Over the past 3 months, 5 analysts have published their opinion on 89bio (NASDAQ:ETNB) stock. These analysts are typically employed by ...

The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data
29 Jun, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eli Lilly To Supply ...

89bio Posts Promising Pegozafermin Data For Severe Hypertriglyceridemia
29 Jun, 2022 FinancialContent

89bio Inc(NASDAQ: ETNB)announced topline resultsfrom the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for ...

U.S. Stock Futures Edge Higher; GDP Report In Focus
29 Jun, 2022 FinancialContent

Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the Dow Jones dropped around 500 points in ...

McCormick, General Mills And 3 Stocks To Watch Heading Into Wednesday
29 Jun, 2022 FinancialContent

Some of the stocks that may grab investor focus today are: Wall Street expects General Mills, Inc. (NYSE: GIS) to report ...

89bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
29 Jun, 2022 Yahoo! Finance

SAN FRANCISCO, June 29, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of its previously announced underwritten public offering of 18,675,466 shares of its common stock and accompanying warrants to purchase up to 9,337,733 shares of common stock at a combined public offering price

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock, Pre-Funded Warrants and Warrants
28 Jun, 2022 Yahoo! Finance

SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock,

89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
28 Jun, 2022 Yahoo! Finance

- Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW dose; p

89bio to Present Additional Pegozafermin Data at EASL International Liver Congress™ 2022
21 Jun, 2022 Yahoo! Finance

SAN FRANCISCO, June 21, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data in non-alcoholic steatohepatitis (NASH) will be presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022, to be held in London, UK on June 22-26, 2022. Pr

Look Under The Hood: RYJ Has 63% Upside
21 Jun, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Raymond James SB-1 Equity ETF (RYJ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $82.00 per unit.

89bio Pulls Back With Market — But Could The Stock Soar 250%?
10 Jun, 2022 FinancialContent

89bio, Inc (NASDAQ: ETNB) was plunging almost 10% lower on Friday in sympathy with the general market, which saw the S&P 500 ...

2 “Strong Buy” Penny Stocks That Could Rally All the Way to $30 (Or More)
02 Jun, 2022 Yahoo! Finance

There are two sides to every coin. For penny stocks, or tickers that trade for less than $5 per share, this rings especially true. As some of the most divisive names on the Street, they are either met with resounding praise or forceful discontent. Going beyond the argument that you get more for your money, even minor price appreciation can result in massive percentage gains. However, some investors prefer to avoid these stocks entirely, as the fact that shares are trading at such depressed level

Analysts Anticipate IBBQ To Hit $29
20 May, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Nasdaq Biotechnology ETF (IBBQ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $29.44 per unit.

Analyst Ratings for 89bio
13 May, 2022 FinancialContent

89bio (NASDAQ:ETNB) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...

10 Biggest Price Target Changes For Friday
13 May, 2022 FinancialContent

Barclays cut the price target on Avis Budget Group, Inc. (NASDAQ: CAR) from $245 to $223. Avis Budget shares rose 2.3% to $224.98 ...

90 Biggest Movers From Yesterday
13 May, 2022 FinancialContent

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) surged 70.5% to close at $0.1330 on Thursday after declining 9% on Wednesday. ...

12 Health Care Stocks Moving In Thursday's Intraday Session
12 May, 2022 FinancialContent

Gainers Allena Pharma (NASDAQ:ALNA) shares moved upwards by 103.7% to $0.16 during Thursday's regular session. As of ...

58 Stocks Moving In Thursday's Mid-Day Session
12 May, 2022 FinancialContent

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 102.6% to $0.1580 after declining 9% on Wednesday. Allena ...

89bio, Inc (ETNB) is a NASDAQ Common Stock listed in , ,

970x250